(Q39150078)

English

TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells

scientific article published on 18 May 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 September 2017

TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells (English)

1 reference

Europe PubMed Central

9 September 2017

toll-like receptor

0 references

1 reference

based on heuristic

inferred from title

head and neck cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

head and neck carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Robert L Ferris

6

1 reference

Europe PubMed Central

9 September 2017

author name string

Ryan M Stephenson

1

1 reference

Europe PubMed Central

9 September 2017

Chwee Ming Lim

2

1 reference

Europe PubMed Central

9 September 2017

Maura Matthews

3

1 reference

Europe PubMed Central

9 September 2017

Gregory Dietsch

4

1 reference

Europe PubMed Central

9 September 2017

Robert Hershberg

5

1 reference

Europe PubMed Central

9 September 2017

publication date

18 May 2013

1 reference

Europe PubMed Central

9 September 2017

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

9 September 2017

62

1 reference

Europe PubMed Central

9 September 2017

8

1 reference

Europe PubMed Central

9 September 2017

1347-1357

1 reference

Europe PubMed Central

9 September 2017

https://scigraph.springernature.com/pub.10.1007/s00262-013-1437-3

0 references

Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

10 September 2017

The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

10 September 2017

Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

10 September 2017

Tumor antigen cross-presentation and the dendritic cell: where it all begins?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

10 September 2017

Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

10 September 2017

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

10 September 2017

Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

10 September 2017

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

10 September 2017

The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

10 September 2017

Recognition of viral single-stranded RNA by Toll-like receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

10 September 2017

TLR7 and TLR8 as targets in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

10 September 2017

Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

10 September 2017

Imiquimod: in superficial basal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

10 September 2017

Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

10 September 2017

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

10 September 2017

Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

10 September 2017

Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

10 September 2017

Cloning of a new cytokine that induces IFN-gamma production by T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

10 September 2017

Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

14 September 2017

Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

14 September 2017

Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

14 September 2017

First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

14 September 2017

TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

14 September 2017

VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

17 June 2018

An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

17 June 2018

Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

21 August 2018

Human dendritic cells stimulated via TLR7 and/or TLR8 induce the sequential production of Il-10, IFN-gamma, and IL-17A by naive CD4+ T cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

21 August 2018

T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

21 August 2018

The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720845

21 August 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/23685782

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23685782

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects

1 reference

https://pubmed.ncbi.nlm.nih.gov/23685782

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00262-013-1437-3

1 reference

Europe PubMed Central

9 September 2017

1 reference

Europe PubMed Central

9 September 2017

1 reference

Europe PubMed Central

9 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39150078&oldid=1809647032"